» Employer Profile

UCB Pharma

For a medium-sized company, we have not only had an unusually large impact, but also demonstrated our ability to re-invent ourselves. Strong and geographically balanced, long-term growthSince the 1950s, when we entered the pharmaceutical market, our revenues have grown solidly and now stand at around €3.5 billion, increasing by 11% in 2006. The United States accounts for over 45% of our sales, followed by Europe (42%) and Japan (5%). Emerging markets, such as China and India (8%), have grown significantly, up 24% in 2006.A world leader in epilepsy and allergyThe anti-epileptic, Keppra®, is a market leader in both the United States (29% share) and Europe (26%) and is extending its leadership thanks to the launch of a string of new indications for this global brand – a measure of our ability to optimise the life cycles of our products. Keppra® now has more than 1.5 million years of patient experience. Its main successor, brivaracetam, promises to make greater headway. The anti-histamine Zyrtec®, remains a market leader in the United States, twenty years after its launch. To further manage this franchise, we recently launched Xyzal® in the United States, under a co-marketing agreement with Pfizer. Xyzal® is already approaching market leadership in Europe and will be launched in the United States with sanofi-aventis during the third quarter of 2007 A leader in antibody research, supported by our Centre of Antibody Excellence, our proprietary SLAM (Selected Lymphocyte Antibody Method) technology, enables us to isolate functionally active antibodies with exceptional speed. A unique, patented expertise in the SV2A protein, which lies at the heart of our family of anti-epileptics. These and other R&D strengths are complemented by more than thirty major scientific and technological partnerships.A rich pipeline of large and small moleculesTwelve molecules, including five large, antibody-based molecules and seven small, chemically-derived molecules, are in clinical development, addressing seventeen different types of severe disease, from multiple sclerosis to rheumatoid arthritis to early Parkinson's disease.A history of re-inventing ourselvesEstablished in Belgium in 1928, UCB originally focused on chemicals, with a small pharmaceutical unit. By the 1950s, it moved more heavily into pharmaceuticals, discovering Atarax®, a non-benzodiapenic tranquiliser. Zyrtec® was launched in 1987 and Keppra® in 1999. We started to transform ourselves into a focused biopharma with large and small molecule therapies in 2004 with the acquisition of the leading UK biotech company Celltech. Chemicals, Films and other non-core assets were sold. In 2006, we filed our most advanced biologic, Cimzia®, for regulatory approval and acquired Schwarz Pharma, strengthening our resources, pipeline and product portfolio, taking us into new fields such as Parkinson’s disease or restless legs syndrome and fibromyalgia. For more detailed insights into our evolution, see our history

» Open Job Vacancies

Job Title:	Location:	Salary:
There are currently no job vacancies advertised by this employer.

« : ‹ : [1] : › : »